The global tuberculosis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is anticipated to augment the market during the forecast period includes an increase in R&D investments and an increase in new drug developments. For instance, a US-based TB Alliance, which is a non-profit organization, has developed a new drug for treating highly drug-resistant forms of tuberculosis. The TB Alliance received the US FDA approval in August 2019, for Pretomnid, a combination regimen with bedaquiline and linezolid, which is developed and indicated for the treatment of patients with XDR-TB, or intolerant non-responsive MDR-TB. 

Further, to commercialize their newly developed drugs, the market players are focusing on strategic collaborations such as partnerships and collaborations, and mergers & acquisitions. For instance, in April 2019, Mylan NV, a pharmaceuticals company, collaborated with TB Alliance to commercialize the Pretomanid drug for treating pulmonary tuberculosis (TB). The other factor that is responsible for fuelling the market growth includes a high prevalence of TB across the globe. For instance, according to the World Health Organisation’s (WHO) global tuberculosis report 2018, around 10 million people globally suffered from Tuberculosis in 2017.

Tuberculosis (TB) is a chronic condition and has become a global disease burden. Manufacturers of TB drugs are focused on developing drugs that can shorten the duration of treatment, and support overcoming the challenges of drug-susceptible TB and drug-resistant TB. The treatment of TB is divided into three types, such as first-line therapy, second-line therapy, and combination therapy. Moreover, the other factor that is expected to propel the market growth includes the advent of novel therapies that are expected to improve the duration of treating TB. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Johnson & Johnson Services, Inc., Lupin Ltd, Novartis International AG, Otsuka Pharmaceutical Co., Ltd, and Pfizer Inc.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tuberculosis Drugs Market Report by Segment

By Therapy

• First-Line Therapy

• Second-Line Therapy

• Combination Therapy

By Disease Type

• Latent Tuberculosis

• Active Tuberculosis

Global Tuberculosis Drugs Market by Region